ClinicalTrials.gg
CompletedNCT00399477Updated Apr 12, 2011

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

A Phase 4 interventional study of rasagiline mesylate and Rasagiline mesylate plus Mirapex in Parkinson's Disease, sponsored by Teva Neuroscience, Inc.. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Teva Neuroscience, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing rasagiline in Parkinson Disease — none open to participants now, none under way, none of them phase 3. rasagiline · Parkinson Disease.

Enrollment
14th of 37
200 · median 121
Started
2006
the only one that year
Phase 4
16 of 37
none open now
Registered
8th of 37
by date
Lead sponsor
3 of 37
Teva Neuroscience, Inc.

Among the 37 studies testing rasagiline in Parkinson Disease, this one is the 14th largest by enrollment, is the only one that started in 2006, is one of 16 in phase 4, and was the 8th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 37 studies testing rasagiline in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About rasagiline

rasagiline: first FDA approval 2006 (AZILECT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing rasagiline in Parkinson Disease as a file.
02

Study summary

Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:

  • Group 1 Patients using Azilect and no other therapy.
  • Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Idiopathic Parkinson's disease. Diagnosis previously confirmed by the presence of bradykinesia and by at least one additional cardinal sign (i.e., resting tremor, rigidity), without other known or suspected cause of parkinsonism.
  2. Requiring therapy for PD symptom control

    • Azilect monotherapy.
    • Azilect as adjunct therapy..

Exclusion criteria

Exclusion Criteria:

  1. Patients previously exposed to Azilect
  2. Patients with pheochromocytoma
  3. Concomitant MAO inhibitors or medications for use with MAO inhibitors are not allowed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Rasagiline mesylate

    Drug: rasagiline mesylate

  • Experimental
    Rasagiline mesylate plus adjunct therapy

    Rasagiline mesylate with one of three adjunct therapies

    Drug: Rasagiline mesylate plus Mirapex · Drug: Rasagiline mesylate with Levodopa · Drug: Rasagiline mesylate with Requip

Interventions

06

What researchers measure

Primary outcomes

  1. To identify the earliest scheduled visit of symptomatic effect

    Time frame: 8 months

Secondary outcomes

  1. To characterize the effectiveness of Azilect in a usual community neurological

    Time frame: 8 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2006
First posted
Nov 14, 2006
Start
Oct 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00399477
First posted
Nov 14, 2006
Start date
Oct 2006
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Apr 12, 2011

Study contacts

MerriKay Oleen-Burkey, PhD
study director · Teva Neuroscience, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rasagiline · Pramipexole · Levodopa · Ropinirole

Start the discussion